Clinical trials: Dry Eye Symptoms
Ocular Pain, Dry Eye
Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers
The purpose of this study is to determine whether SYL1001 is safe for the prevention and treatment of ocular pain and dry eye syndrome.
- Trial name
- NCT01438281
- Testing
- SYL1001
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sylentis, S.A.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Sjögren´s Disease
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
- Trial name
- THALASSA (NCT07621809)
- Testing
- VAY736
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 570 people
- Sponsor
- Novartis Pharmaceuticals
Ocular Pain, Dry Eye Syndrome
Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain
The aim of this pilot study is to compare the analgesic effect of two strengths of SYL1001 eye drops versus placebo in patients with ocular pain associated with Dry Eye Syndrome. General and local tolerability are also evaluated.
- Trial name
- NCT02455999
- Testing
- SYL1001
- Where
- 6 sites in Estonia, Spain
- Volunteers
- 66 people
- Sponsor
- Sylentis, S.A.
Long Term Follow up Dry Eye Disease
Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
The objective of this safety long-term follow-up study was to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study (NCT03636061).
- Trial name
- NCT03920215
- Testing
- OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Oyster Point Pharma, Inc.
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease (DED)
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
- Trial name
- NCT03333057
- Testing
- NOV03
- Where
- 11 sites in United States
- Volunteers
- 336 people
- Sponsor
- Novaliq GmbH
Dry Eye Syndromes, Eye Diseases
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED
- Trial name
- NCT05814757
- Testing
- OTX-DED, Controlled Insertion, Collagen Punctal Plug
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ocular Therapeutix, Inc.
Age-related Macular Degeneration
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received…
- Trial name
- FALCON (NCT04679935)
- Testing
- Brolucizumab
- Where
- 19 sites in Germany, Switzerland
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye, Dry Eye Syndrome (DES)
Post-marketing Study Focused on Evaluating I+Med's DayDrop for Improving Signs and Symptoms of Mild/Moderate Dry Eye
Clinical post-marketing quasi-experimental before-and-after trial to determine the effectiveness of DayDrop treatment in subjects seeking relief from symptoms of dryness and eye irritation based on OSDI questionnaire scores…
- Trial name
- NCT06731725
- Testing
- DayDrop®
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- i+Med S.Coop.
Retinal Disease, Macular Degeneration
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
- Conditions
- Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy
- Trial name
- NCT06394232
- Testing
- Eyecyte-RPE™
- Where
- 3 sites in India
- Volunteers
- 54 people
- Sponsor
- Eyestem Research Pvt. Ltd.
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID.
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjogren's Syndrome
- Trial name
- NCT06417398
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Dry Eye Syndromes
Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms
This study evaluates the performance and acceptance of Optive versus Hylocomod eyedrops, when administered for one month to patients with mild to moderate dry eye symptoms, with and without contact lenses.
- Trial name
- NCT00761202
- Testing
- A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®, Sodium hyaluronate
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Allergan
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Treatment of Dry Eye Disease With Meibomian Gland Dysfunction
Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction
The study is being conducted to evaluate the efficacy and safety of SHR8058 eye drops for patients with dry eye disease.
- Trial name
- NCT05515471
- Testing
- SHR8058 eye drops, saline eye drops.
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Dry Eye
Artificial Tears Study in Mild to Moderate Dry Eye Patients
The mean change in the subjective comfort score from baseline of the test group is at least 2.0 units less than that of the control group.
- Trial name
- NCT00607776
- Testing
- (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400, Systane
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Abbott Medical Optics
Dry Eye Disease
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
- Trial name
- NCT07128628
- Testing
- Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane
- Where
- 32 sites in United States
- Volunteers
- 443 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Syndromes
Randomized Study of the Safety and Effectiveness of the TearCare System for the Signs and Symptoms of Dry Eye Disease
In this study, the TearCare System will be compared with standard-of-care warm compress treatment and lid massage in patients with dry eye disease.
- Trial name
- NCT03502447
- Testing
- TearCare, Warm Compress and Lid Massage
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sight Sciences, Inc.
Myopia
A Prospective Study of Two Daily Disposable Contact Lenses
The purpose of this study was to evaluate the performance of a novel silicone hydrogel contact lens, DAILIES TOTAL1® (DT1) compared to the standard hydrogel material in 1-DAY ACUVUE® MOIST® (1DAVM) contact lens in contact lens…
- Trial name
- NCT01636986
- Testing
- Delefilcon A contact lenses, Etafilcon A contact lenses
- Volunteers
- 62 people
- Sponsor
- Alcon Research